Who is involved
Before the emergence of the Cicada variant, designated BA.3.2, the COVID-19 situation in the UK and globally had been relatively stable, with vaccinations reducing severe cases and hospitalizations. The public health focus was primarily on managing existing variants, particularly those within the Omicron family, which had shown a degree of resistance to vaccines but were not associated with significant increases in hospitalizations or deaths. The expectation was that the ongoing vaccination campaigns would continue to keep severe cases at bay.
However, the detection of the Cicada variant in the UK marked a decisive moment in the pandemic. First identified in South Africa in November 2024, this variant has since spread to 23 countries, including the UK. As of March 2026, it was reported that the Cicada variant accounts for approximately 30% of COVID-19 sequences in Denmark, Germany, and the Netherlands, indicating a rapid spread across Europe. The variant carries 70 to 75 genetic changes in its spike protein, which raises concerns about its potential to evade immunity from previous infections and vaccinations.
The immediate effects of the Cicada variant have been felt across the healthcare system. Symptoms associated with this variant include a particularly painful sore throat, fever, cough, fatigue, and nasal congestion. While there is no evidence suggesting that the Cicada variant causes more severe disease than previous variants, its rapid spread and the possibility of reduced vaccine efficacy have prompted health officials to reassess public health strategies. The current COVID-19 vaccine may be less effective against the Cicada variant due to its significant genetic differences, raising alarms among healthcare professionals and the public alike.
Expert voices have weighed in on the implications of the Cicada variant. Kyle B. Enfield, an infectious disease expert, noted, “Because it’s significantly different, the current COVID-19 vaccine may not be as effective.” Ian Budd, another expert in virology, emphasized the importance of the variant’s mutations, stating, “What’s different about it is the number of mutations it carries, particularly on the part of the virus that attaches to your cells.” These insights highlight the need for ongoing research and monitoring of the variant’s impact on public health.
Moreover, the Centers for Disease Control and Prevention (CDC) has indicated that the Cicada strain “could be associated with seasonal increases in COVID-19 activity.” This suggests that the variant may not only pose immediate risks but could also influence future trends in COVID-19 cases, especially during peak respiratory virus seasons. As the UK navigates this new challenge, the public health response will need to adapt to the evolving landscape of the pandemic.
As of February 2026, the Cicada variant has been confirmed in 24 countries, and its ability to evade antibodies is likely due to the mutations in its spike protein. This raises uncertainties regarding the long-term effectiveness of current vaccines against this variant. Details remain unconfirmed, and the exact impact of the Cicada variant on public health is still being assessed, particularly in countries with limited genomic detection and surveillance capacities.
In summary, the emergence of the Cicada variant in the UK has shifted expectations regarding COVID-19 management. While it does not appear to cause more severe disease than previous variants, its genetic differences and rapid spread necessitate a reevaluation of vaccination strategies and public health measures. The ongoing situation underscores the importance of vigilance and adaptability in the face of an ever-evolving virus.